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Background: We conducted an independent external validation of three cardiovascular risk score models
(Framingham risk score model and SCORE risk charts developed for low-risk regions and high-risk regions in Europe)
on a prospective cohort of 4487 Australian women with no previous history of heart disease, diabetes or stroke.
External validation is an important step to evaluate the performance of risk score models using discrimination and
calibration measures to ensure their applicability beyond the settings in which they were developed.
Methods: Ten year mortality follow-up of 4487 Australian adult women from the National Heart Foundation third
Risk Factor Prevalence Study with no baseline history of heart disease, diabetes or stroke. The 10-year risk of
cardiovascular mortality was calculated using the Framingham and SCORE models and the predictive accuracy of
the three risk score models were assessed using both discrimination and calibration.
Results: The discriminative ability of the Framingham and SCORE models were good (area under the curve > 0.85).
Although all models overestimated the number of cardiovascular deaths by greater than 15%, the
Hosmer-Lemeshow test indicated that the Framingham and SCORE-Low models were calibrated and hence
suitable for predicting the 10-year cardiovascular mortality risk in this Australian population. An assessment of the
treatment thresholds for each of the three models in identifying participants recommended for treatment were found
to be inadequate, with low sensitivity and high specificity resulting from the high recommended thresholds. Lower
treatment thresholds of 8.7% for the Framingham model, 0.8% for the SCORE-Low model and 1.3% for the SCORE-High
model were identified for each model using the Youden index, at greater than 78% sensitivity and 80% specificity.
Conclusions: Framingham risk score model and SCORE risk chart for low-risk regions are recommended for use in the
Australian women population for predicting the 10-year cardiovascular mortality risk. These models demonstrate good
discrimination and calibration performance. Lower treatment thresholds are proposed for better identification of
individuals for treatment.
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Cardiovascular disease (CVD) is one of the leading causes
of death worldwide and in Australia [1,2]. There were
45622 CVD deaths recorded in 2011, more deaths oc-
curred in Australian females (23755) than Australian males
(21867) [2]. Effective primary prevention strategies targeted
at the individuals “at risk” are needed to reduce the num-
ber of CVD deaths [3]. The recent American College of
Cardiology and American Heart Association guidelines [4]
stress that both primary and secondary prevention should
be directed at those most likely to benefit.
Multivariable CVD risk score models enable the quanti-
fication of CVD risk. These models determine the prob-
ability of an individual experiencing a CVD event within a
predefined time period by assessing the entire risk-factor
profile [5]. It identifies “at risk” individuals for intervention
and is a cost-effective approach to CVD prevention [6].
The 2010 American College of Cardiology Foundation
and American Heart Association Guidelines [7] recom-
mends all asymptomatic women to undergo a global CVD
risk assessment. CVD risk factors for women include age,
race/ethnicity, obesity, poor diet, excessive alcohol con-
sumption, physical inactivity, smoking, high blood pres-
sure, high cholesterol, diabetes, chronic kidney disease,
genetics, coronary artery calcium and psychological fac-
tors, and also the interactions between some of these risk
factors [8,9]. It should be noted that not all of these risk
variables have been incorporated into risk score models.
Recommended treatment thresholds are used to identify
individuals at increased CVD risk for treatment.
Commonly used risk score models and treatment
thresholds include, the Framingham risk score model for
10-year CVD incidence or death [10] (20% treatment
threshold) [11,12], SCORE risk chart for 10-year CVD
death (3%, 5%, 7% and 10% treatment thresholds) [13],
Reynolds risk score model for 10-year CVD incidence and
death [14], ASSIGN risk score model for 10-year CVD in-
cidence and death (20% treatment threshold) [12], general
CVD risk score model for 10-year CVD incidence and
death [15] (10% and 20% thresholds) [16,17], simplified
general CVD risk score model for 10-year CVD incidence
and death [15] (10% and 20% thresholds) [16,17] and
QRISK score model for 10-year CVD incidence and death
[18]. These risk score models were developed in the USA
(Framingham, Reynolds and general CVD) and Europe
(SCORE, ASSIGN and QRISK). Age, sex, systolic blood
pressure (SBP), total cholesterol (TC) level, high-density
lipoprotein cholesterol (HDL-C) level and smoking status
were included in all six models. Diabetes status was in-
cluded in all the models except the SCORE model. The
Reynolds risk score model was the only model initially de-
veloped from a female population and it contains bio-
markers in its calculation of the 10-year CVD risk [14].
The QRISK score model includes more risk variables i.e.body mass index (BMI) (which is also found in a simpler
version of the general CVD risk score model), family his-
tory (also found in the Reynolds and ASSIGN model),
Townsend deprivation score (a measure of social
deprivation is also found in the ASSIGN model), use of
antihypertensive medication (also found in the general
CVD model), self-assigned ethnicity, rheumatoid arthritis,
chronic renal disease and atrial fibrillation, compared with
other models [18].
The Framingham and SCORE models were selected
and validated in this study as they have similar end-
points. Both models predict 10-year CVD death risk. In
addition, the risk variables used to calculate the 10-year
CVD risk for the Framingham and SCORE models were
collected in the National Heart Foundation (NHF) Risk
Factor Prevalence Study. Some risk score models did not
have recommended treatment thresholds for identifying
women at increased risk of CVD and their performance
could not be assessed.
Performance of risk score models is typically overesti-
mated in the original data which they were developed
[19]. External validation is an important step to evaluate
the performance of risk score models using discrimin-
ation and calibration measures to ensure their applic-
ability beyond the settings in which they were
developed. The Framingham, SCORE and general CVD
risk score models have been utilised to predict risk in an
Australian population [20,21]. Risk score models have
also been developed for use in Australia i.e. from the
Busselton Health Study and Dubbo Study. These models,
however, are limited in applicability. The former model
predicts the risk of coronary heart disease (CHD) hos-
pitalisation or death while the latter predicts the CVD
risk of older Australians aged 60 years and older [22,23].
The National Vascular Disease Prevention Alliance
recommends the use of the Framingham risk score
model for estimating the 5-year CVD risk of disease-free
Australians and an individual with a risk score of more
than 15% is identified as high risk of developing CVD
and is targeted for treatment [24].
The objective of this study was to conduct an inde-
pendent external validation of the Framingham risk
score model, SCORE model for low-risk regions (which
was developed from European countries with low CVD
rates: Belgium, Italy and Spain) and SCORE model for
high-risk regions (European countries with high CVD
rates: Denmark, Finland and Norway), using a mortality
follow-up cohort of 4487 Australian women from the
NHF Risk Factor Prevalence Study.
Methods
Study participants
Participants were selected from the NHF third Risk Factor
Prevalence Study, 1989 [25]. Residents on the federal
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ney, Melbourne, Brisbane, Adelaide, Perth, Hobart, Dar-
win and Canberra were recruited for the Risk Factor
Prevalence Study by systemic probability sampling of sex
and 5-year age groups. A representative sample of 4487
women aged 20–69 years with no previous history of heart
disease, diabetes or stroke at baseline were included for
analysis. Participants taking medications to reduce their
CVD risk factors were excluded.
Ethics statement
Ethical approval for the NHF data was obtained in ad-
vance from the Australian Institute of Health Interim
Ethics Committee, after consultation with the Com-
monwealth Privacy Commissioner. Participation was
entirely voluntary. Those who participated signed an in-
formed consent form [25]. Participant information was
anonymised prior to analysis. This study was approved
by the Human Research Ethics Committee at Curtin
University. The linkage and analysis of the NHF data
with the National Death Index were approved by the
current Ethics Committee of the Australian Institute of
Health and Welfare (AIHW), and complies with the
Declaration of Helsinki.
Risk factor measurements
A self-administered questionnaire was completed and
information on demographic and clinical characteristics
and smoking status were collected. Physical measure-
ments were also taken: weight (to the nearest tenth of
a kilogram), height (to the nearest centimetre), waist cir-
cumference and hip circumference were measured twice
to the nearest centimetre according to standardised
methodologies [26,27], and systolic and diastolic blood
pressure were recorded on the right arm of seated par-
ticipants five minutes apart using mercury sphygmoma-
nometers. The average of the two readings of blood
pressure was used in the analysis [25]. Fasting blood
samples were also collected in EDTA tubes and des-
patched to the central laboratory at the Division of Clin-
ical Chemistry, Institute of Medical and Veterinary
Science, Adelaide each week for cholesterol levels to be
assayed. Participants were classified as non-smokers,
previous smokers or current smokers [25].
Cardiovascular disease outcomes
Mortality was ascertained to 31 December 1999 using
the National Death Index maintained by the AIHW. The
demographic data of the participants who were free from
CVD and diabetes at baseline were submitted to AIHW.
These data were then matched with the National Death
Index using a probabilistic record linking package
(“Automatch”). This provided data on the 10 year mor-
tality follow-up. Causes of death were coded accordingto the International Classification of Diseases (ICD) 9th
or 10th revision. ICD-9 codes 3900–4589 or ICD-10
codes I00.0-I99.9 were used for CVD deaths [28,29]. The
calculation of 10-year CVD risk from baseline data en-
abled assessment and comparison of the three risk score
models and CVD death events were used because these
events were determined, unlike non-fatal CVD events
which are usually self-reported [9].
Risk score models
The Framingham risk score model predicts the 10-year
risk of CVD death [10]. It was developed using partici-
pants aged 30–74 years who were free of CVD and can-
cer from the American Framingham Heart Study. Age,
sex, SBP, diastolic blood pressure, TC level, HDL-C level,
smoking status and diabetes status were used in the
calculation of the 10-year CVD risk [10]. Although
electrocardiogram-left ventricular hypertrophy (ECG-
LVH) is included in the Framingham model for the calcu-
lation of the 10-year CVD risk, participants were assumed
not to have LVH as ECG was not undertaken in the NHF
third Risk Factor Prevalence Study. The most commonly
used treatment threshold for the Framingham risk score
model was 20% [9]. This denotes that an individual who
has a risk score of more than 20% is considered to be “at
risk” of experiencing a CVD event within the next 10 years
and should be targeted for treatment. Treatment includes
lifestyle intervention (quit smoking, diet and exercise) as
well as drug therapy (for lipids, hypertension and dia-
betes). Later versions of the Framingham risk score
models include the National Cholesterol Education Pro-
gram’s Third Adult Treatment Panel (ATP-III) risk assess-
ment tool for the prediction of 10-year CHD risk, general
CVD risk score model to predict the 10-year risk of
CVD incidence and death and the Framingham risk pre-
diction algorithm to quantify the 30-year risk of CVD
[15,30-33]. A new sex- and race-specific risk equation for
predicting the 10-year atherosclerotic CVD risk, for fatal
and non-fatal CVD events, for African-American and
White men and women aged 40–79 years has also been
published in the 2013 American College of Cardiology
Foundation and American Heart Association Guidelines
on the Assessment of Cardiovascular Risk [4].
The SCORE risk chart was developed by pooling 12
cohort studies in Europe. Participants aged 19–80 years
with no previous history of heart attack were included in
model development [13]. Cohorts in Denmark, Finland
and Norway were used to develop the SCORE risk chart
for high-risk regions as they reported higher CVD rates,
adjusted for risk factor levels, age [34], cohort sizes and
data availability while cohorts in Belgium, Italy and
Spain were used for low-risk regions [13]. Fewer risk
variables were used to calculate the 10-year risk of CVD
death with the SCORE risk chart for low-risk and high-
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ger cohort was used to develop the SCORE risk chart
than the Framingham model. Age, sex, mean SBP, mean
TC level, mean HDL-C level and smoking status were
included in the calculation of the 10-year risk of CVD
death for the SCORE models. Commonly used treatment
thresholds for the SCORE risk chart included 3% and
5% for low-risk regions, and 3%, 5%, 7% and 10% for
high-risk regions [13].
Statistical analysis
The data on the representative sample of 4487 Australian
females were described using mean ± standard deviation
or median (inter-quartile range) for continuous variables,
while counts and percentages were used for categorical
variables. Ten-year predicted CVD mortality risk was cal-
culated for each participant using the Framingham and
the two SCORE risk models and these were compared
against observed actual CVD mortality. The predictive ac-
curacy of the CVD risk score models were assessed using
both discrimination and calibration.
Calibration was assessed by ranking the cohort into
quintiles of risk and comparing the number of predicted
and observed deaths within each quintile. The Hosmer-
Lemeshow chi-squared goodness-of-fit test was used to
measure the agreement between predicted and observed
events across the quintiles of predicted risk for each of
the models [35]. A chi-squared p-value that is greater
than 0.05 indicates a well-calibrated model. Graphically,
calibration is represented as a plot of observed and pre-
dicted risk by quintiles of risk, arranged from low risk to
high risk as determined by the CVD risk score models.
Discrimination was assessed by plotting the receiver
operating characteristic (ROC) curve and calculating the
area under the ROC curve (AUC) or c statistic. The
ROC curve is a plot of true positives (sensitivity) against
false positives (1-specificity) that provides a summary of
sensitivity and specificity across a range of cut points for
a continuous predictor [36]. The c statistic refers to the
probability that the predicted risk is higher for a case
than for a non-case and a c statistic of 1 indicates per-
fect discrimination and the predicted risks are higher
for all cases than non-cases even if the predicted risk
score differs from the observed risk [36-38]. Sensitivity,
specificity, likelihood ratio and Youden index [39] were
calculated at the respective recommended treatment
thresholds of the risk score models, and at the proposed
cut-off. P-values of less than 0.05 were considered to be
statistically significant. All statistical analyses were per-
formed with IBM SPSS Statistics Version 21.
Results
The demographic and clinical characteristics of the cohort
of 4487 women without baseline heart disease, diabetes orstroke are presented in Table 1. The predicted 10-year
CVD death risk calculated using the Framingham risk
score model, and SCORE risk chart for low-risk and high-
risk regions are also presented. There were 152 deaths
from all causes and 28 deaths due to CVD observed dur-
ing the 10 years of follow-up. These 152 deaths repre-
sented approximately 3.4% of the sample and 0.3% of the
total deaths in the Australian female population in 1989
[40], at the start of the study, and 0.2% in 1999 [41], at the
end of the 10-year follow-up.
In Figure 1, the observed 10-year CVD death risk is
compared with the Framingham, SCORE-Low and
SCORE-High predicted risks across the range of ages in
the cohort. The risk score models generally underesti-
mated the 10-year CVD death risk in those below 50 years
of age and overestimated the risk in those aged 50 years
and above. The Framingham risk score model and SCORE
risk chart for low-risk regions predicted similar risk
levels in the age categories while the SCORE-High
model predicted higher risk levels compared to the
other two models.
The Framingham, SCORE-Low and SCORE-High risk
score models accurately predicted the 10-year risk of
CVD death in the first four quintiles of risk (Figure 2).
For the highest quintile of risk, however, all three models
overestimated the 10-year risk. The overestimation was
higher in the SCORE-High model than the Framingham
and SCORE-Low models.
Table 2 presents the discrimination and calibration
model performance statistics for the Framingham,
SCORE-Low and SCORE-High models. The ratio of the
10-year CVD predicted risk to the observed risk in the
highest quintile was 1.41 for the Framingham model,
1.35 for the SCORE-Low model and 2.02 for the
SCORE-High model. The observed number of deaths is
28 (Table 2). The Framingham risk score model pre-
dicted the total number of deaths to be 34.5, an overesti-
mation of approximately 23%. The SCORE-Low model
predicted the total number of deaths to be 32.5, an over-
estimation of about 16% while the SCORE-High model
overestimated the number of CVD deaths by approxi-
mately 75%. Calibration, as assessed using the Hosmer-
Lemeshow test, indicated that the overestimation was
not significant for the Framingham and SCORE-Low
models and that the models were calibrated. All models
reported high ROC AUC (≥0.858).
Cut-points of the risk score models were identified
from a review of the literature and their respective sensi-
tivity, specificity, likelihood ratio and Youden index are
reported (Table 3). Low sensitivities were observed for
the cut-points from the literature, with the Framingham
risk score model reporting 0% sensitivity at the 20% cut-
point. Lower cut-points were identified at the maximal
Youden index. The proposed cut-points are 8.7% for the
Table 1 Characteristics of the cohort of 4487 women without heart disease, diabetes or stroke at baseline
Variables Total cohort Survivors Deaths (all-cause) CVD deaths
n = 4487 n = 4335 n = 152 n = 28
Age (years) 42.8 ± 13.2 42.3 ± 13.0 56.0 ± 11.9 60.8 ± 8.1
BMI (kg/m2) 24.8 ± 4.7 24.8 ± 4.7 26.2 ± 5.0 26.5 ± 3.8
WC (cm) 76.2 ± 11.1 76.0 ± 11.0 81.2 ± 10.7 82.5 ± 10.3
WHR 0.76 ± 0.06 0.76 ± 0.06 0.79 ± 0.07 0.80 ± 0.06
SBP (mmHg) 122.1 ± 18.4 121.6 ± 18.0 134.2 ± 23.4 143.7 ± 29.4
TC (mmol/L) 5.5 ± 1.2 5.4 ± 1.1 6.0 ± 1.2 6.5 ± 1.2
HDL-C (mmol/L) 1.5 ± 0.4 1.5 ± 0.4 1.5 ± 0.4 1.5 ± 0.4
Ratio of TC to HDL-C 3.9 ± 1.3 3.9 ± 1.3 4.3 ± 1.5 4.9 ± 2.2
Non-smoker 2652 (59.1%) 2570 (59.3%) 82 (54.0%) 13 (46.4%)
Previous smoker 880 (19.6%) 854 (19.7%) 26 (17.1%) 4 (14.3%)
Current smoker 955 (21.3%) 911 (21.0%) 44 (28.9%) 11 (39.3%)
FPR (%) 0.8 ± 1.8 0.7 ± 1.7 2.9 ± 3.7 5.2 ± 5.8
SCORE-Low (%) 0.7 ± 1.9 0.7 ± 1.6 3.1 ± 5.2 6.1 ± 9.9
SCORE-High (%) 1.1 ± 2.8 1.0 ± 2.4 4.5 ± 7.3 8.9 ± 13.8
FPR (%) 0.1 (0 , 0.6) 0.1 (0 , 0.5) 1.5 (0.2 , 4.1) 3.1 (1.0 , 6.6)
SCORE-Low (%) 0.1 (0 , 0.6) 0.1 (0 , 0.5) 1.8 (0.2 , 3.7) 2.9 (1.0 , 5.7)
SCORE-High (%) 0.1 (0 , 0.9) 0.1 (0 , 0.8) 2.8 (0.4 , 5.6) 4.3 (1.5 , 8.6)
Abbreviations: BMI, body mass index; WC, waist circumference; WHR, waist to hip ratio; SBP, systolic blood pressure; TC, total cholesterol; HDL-C, high-density
lipoprotein cholesterol; FPR, Framingham 10-year predicted risk for CVD death; SCORE-Low, SCORE-Low 10-year predicted risk for CVD death; SCORE-High,
SCORE-High 10-year predicted risk for CVD death.
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and 1.3% for the SCORE-High model, to identify those
at an increased 10-year CVD death risk, at greater than
78% sensitivity and 80% specificity.
Discussion
In this cohort of 4487 Australian females, the Framing-
ham, SCORE-Low and SCORE-High models performed
well in discriminating those who died from CVD from
those who did not. However, only the Framingham
and SCORE-Low models indicated that they were well-
calibrated (p > 0.05) in this population, although risk was
generally overestimated. The calibration statistics reportedFigure 1 Comparison of predicted and observed 10-year CVD death r
predicted risk – green line, SCORE-High predicted risk – purple line and obserin previous study also indicated that the Framingham
model was well-calibrated, consistent with our study, but
not the SCORE risk chart [20].
Overestimation was observed in the highest risk quin-
tile in our study, where the ratio of the 10-year CVD
predicted risk to the observed risk was 1.41 for the Fra-
mingham risk score model, 1.35 for the SCORE-Low
model and 2.02 for the SCORE-High model. It had also
been suggested previously that the accuracy of risk pre-
diction at the extremes of risk needs to be improved
[42]. A systematic review study on the external valid-
ation of the Framingham risk score model for predicting




isk by age category. (Framingham predicted risk – red line, SCORE-Low
ved risk – black dotted line).
Predicted risk
Observed risk
Figure 2 Comparison of predicted and observed 10-year CVD death risk by quintiles of risk (Predicted risk – red line and observed
risk – black dotted line).
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under-prediction of 0.43 in a high-risk population to an
over-prediction of 2.87 in a lower-risk population [43].
There was a similar trend for the prediction of 10-year
CVD risk [43]. An under-prediction of risk was reported
in Malaysian women using the SCORE risk chart [44].
In our study, the Framingham risk score model overes-
timated the total CVD deaths by 23%, the SCORE-Low
model overestimated by about 16% and the SCORE-
High model overestimated the number of CVD deaths
by approximately 75%. In a study of Australian men free
of heart disease, stroke and diabetes, the Framingham
risk score model significantly over-predicted the risk
of CHD and CVD death in all quintiles [45]. A study
on two German prospective cohorts found that the
Framingham predicted risk substantially exceeded the
observed risk in the cohorts, with an overestimation of













ROC AUC (95% CI) 0.858 (0.786 – 0.929)
*An outlier was excluded from quintile 1 (1 death) in the calculation of the Hosmer
would result in the Hosmer-Lemeshow X2 = 14.35, p-value = 0.0025, and the risk sco
woman with elevated risk factors associated with increased CVD risk, on further exa
Abbreviations: FPR, Framingham 10-year predicted risk for CVD death; SCORE-Low,
10-year predicted risk for CVD death; ROC, receiver operating characteristic curve; Aobserved in another study, the expected CHD deaths
was 162, however, only 148 CHD deaths were observed
[47]. A study which compared the performance of the
Framingham model and the SCORE model in predicting
the 10-year CHD and CVD mortality risk in a non-
diabetic population aged 40–65 years from a Spanish
healthcare centre found that the SCORE model over-
predicted the risk by 40% while the Framingham model
over-predicted the risk by 64% (33% in men and 150% in
women) [48]. Using the SCORE risk chart for low-risk
regions to predict the 10-year risk of CVD death, a study
observed that the model over-estimated the CVD mortality
risk in women [49]. Overestimation was also reported for
the SCORE risk chart for high-risk regions and the over-
estimation increased with age in women from Norway,
consistent with our study findings [50]. Similarly, the
Framingham risk score model over-predicted the 5-year
CVD risk (p < 0.05) in the Australian Diabetes, Obesity andfor risk score models in estimating the 10-year risk of
SCORE-Low SCORE-High
Actual Predicted Actual Predicted
0 0.0 0 0.0
0 0.1 0 0.2
2 0.6 2 1.0
5 3.5 5 5.6
21 28.3 21 42.4




0.877 (0.827 – 0.927) 0.877 (0.827 – 0.927)
-Lemeshow test, owing to its undue influence on the test. Including this outlier
re model being assessed as not calibrated. This outlier did not represent a
mination.
SCORE-Low 10-year predicted risk for CVD death; SCORE-High, SCORE-High
UC, area under the curve; CI, confidence interval.
Table 3 Diagnostic measures for the prediction of 10-year CVD death using Framingham, SCORE-Low and SCORE-High
models
Models Cut-point determination Cut-point Sensitivity Specificity Likelihood ratio Youden index
FPR Literature [9] 20.0% 0.0% 100.0% - -
Proposed* 8.7% 78.6% 81.1% 4.15 0.60
SCORE-Low Literature [13] 3.0% 46.4% 93.7% 7.31 0.40
Literature [13] 5.0% 28.6% 97.3% 10.72 0.26
Proposed* 0.8% 82.1% 80.7% 4.27 0.63
SCORE-High Literature [13] 3.0% 60.7% 89.5% 5.78 0.50
Literature [13] 5.0% 35.7% 94.5% 6.47 0.30
Literature [13] 7.0% 28.6% 96.9% 9.17 0.26
Literature [13] 10.0% 17.9% 98.7% 14.01 0.17
Proposed* 1.3% 82.1% 80.8% 4.29 0.63
Abbreviations: FPR, Framingham 10-year predicted risk for CVD death; SCORE-Low, SCORE-Low 10-year predicted risk for CVD death; SCORE-High, SCORE-High
10-year predicted risk for CVD death; proposed*, cut-point identified from our study using the Youden index for high sensitivity and specificity.
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score model [21]. The risk was also overestimated using
the general CVD risk score model. Another study assessed
the performance of the Framingham risk score model and
a general practice model in a cohort of 3582 women aged
60–79 years who were initially free of CHD in the British
Women’s Heart and Health Study and observed that
the Framingham model accurately predicted the 5-year
CHD risk but over-predicted the CVD risk [51]. Similar to
our study, the model overestimated CVD risk in higher-
risk groups. The Framingham risk score model also over-
predicted the 10-year CVD risk in another study by 35%
[52]. It over-estimated the risk less than the ASSIGN
model but more than the QRISK model. Its performance
was also compared with the QRISK score model in two
United Kingdom (UK) cohorts and the Framingham model
over-predicted the risk as well [53].
Similar to our study findings, a systematic review
study which assessed the performance of the Framing-
ham risk score model using 25 validation cohorts of dif-
ferent population groups in the analysis reported that it
accurately predicted CHD risk in populations from the
United States, Australia and New Zealand [54]. In the
Dubbo study, the Framingham risk score model for
CHD risk also accurately predicted the 10-year CHD in-
cidence in men and women aged 60–79 years who were
free of CVD or diabetes at baseline [22]. Another study
comparing the performance of ASSIGN, Framingham
and general CVD risk score models in predicting the
10-year CVD risk in a UK cohort of patients from
general practice reported that the Framingham model
predicted the risk accurately but some over-prediction
was observed in women of higher risk [55]. The Fra-
mingham CVD model was also compared with the ATP-
III score and Reynolds risk score using a case-cohort
sample of the multi-ethnic Women’s Health InitiativeObservational Cohort. Contrary to our study findings,
the calibration performance of the Framingham CVD
and ATP-III models were poor, however, the Reynolds
model was calibrated [56].
It is important to extensively evaluate the applicability
of risk models to each population, in order to avoid
under-prediction or over-prediction [57]. Possible causes
of differences in estimation include differences in the
populations used to develop the risk score models and
different risk variables used to estimate risk. Generally,
age, sex, SBP, TC level, HDL-C level and smoking status
are included into risk score models. The incorporation
of additional risk variables such as race/ethnicity, obes-
ity, poor diet, excessive alcohol consumption, physical
inactivity, chronic kidney disease, family history of CVD,
coronary artery calcium and psychological factors, and
also interactions between some of these risk factors
could improve risk estimation in women. Recalibration
has also been shown to improve the performance of risk
score models after accounting for differences in the preva-
lence of risk factors and underlying CVD rates [58,59].
Another option would be to quantify the amount of over-
estimation and adjust accordingly [46].
Existing studies generally reported good discrimination,
consistent with our study findings. Our study reported
AUC ≥ 0.858. High AUC (0.866) has also been reported
for the Framingham risk score model in predicting CVD
death in Australian men and women [60]. AUC of 0.880
and 0.770 were also reported in women using the
Framingham risk score model for predicting myocardial
infarction and CHD death, in two German prospective
studies [46]. A study also found that the SCORE risk chart
for low-risk regions for predicting the 10-year risk of CVD
death discriminated Austrian women well (AUC = 0.780)
[49]. The discrimination performance of the SCORE risk
chart for high-risk regions to predict the 10-year CVD
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values ranged from 0.660 to 0.720 in women [50]. Another
study which assessed the validity and utility of cardiovas-
cular risk score models in a Malaysian population found
that the Framingham risk score model and SCORE risk
chart for low-risk and high-risk regions demonstrated
good discrimination for predicting the 5-year cardiovascu-
lar mortality risk (AUC ranged from 0.758 to 0.763) in
women [44].
The discriminative ability of the Framingham risk
score model and SCORE risk chart have also been com-
pared to other models. The Framingham risk score
model was evaluated against the general CVD risk score
model in the Australian Diabetes, Obesity and Lifestyle
study and reported an AUC of 0.740, which is lower
than the general CVD risk score model (AUC = 0.760)
[21]. Another study compared the performance of the
Framingham, QRISK and ASSIGN models and reported
that the Framingham model had lower ROC statistic
(0.774) in women than QRISK and ASSIGN models
[52]. Similar results were observed in two UK cohorts
with the Framingham risk score model reporting lower
ROC statistics (approximately 0.776 and 0.760) than the
QRISK score model [53]. The performance of the Fra-
mingham CVD model was also compared with the ATP-
III score and Reynolds risk score in a multi-ethnic
Women’s Health Initiative Observational Cohort. The c
statistics of the Framingham model and ATP-III score
were 0.750 and 0.757, respectively, and were both lower
than the Reynolds model [56].
The threshold discrimination is also an important as-
pect to consider, particularly in clinical practice [61].
The sensitivity and specificity of CVD risk score models
at different cut points or treatment thresholds should be
reported [62]. In our study, participants at increased risk
of CVD were not adequately identified for treatment at
the respective recommended treatment thresholds of the
three risk score models. Low sensitivity and high specifi-
city were reported as the recommended treatment
thresholds were high. The higher treatment thresholds
currently used for risk score models, under-treat individ-
uals in higher risk groups. Our study identified lower
treatment thresholds for the Framingham risk score
model (8.7%) and SCORE risk chart for low- (0.8%) and
high-risk (1.3%) regions, to improve the identification of
individuals who require treatment with high sensitivity
and specificity. Previous studies have also reported that
it is difficult for individuals to exceed the recommended
treatment thresholds even with markedly elevated risk
factors. The Framingham risk score model was com-
pared against the ASSIGN risk score using the Scottish
Heart Health Extended Cohort. At the 20% cut point,
the sensitivity of the Framingham risk score model was
low (45.6%), while the specificity was 82.5% [12]. Inanother study, the Framingham model for predicting the
10-year CHD risk classified only 33% of all CHD events
occurred in women as high risk, using a threshold of
20% [63]. The Framingham risk score model and SCORE
model to predict CVD mortality was also evaluated in
the Netherlands and the Framingham model only identi-
fied 0.7% of the population for treatment while the
SCORE model assigned 0.4% for treatment, at a thresh-
old of 10% [64]. Among those identified for treatment
using the Framingham and SCORE models, their ob-
served risk was 6.2% and 10.2%, respectively, indicating
that the recommended threshold was inadequate for
identifying individuals for treatment. The 10-year pre-
dicted risk was < 10% or low across age groups and risk
factor levels using the ATP-III risk assessment tool [32].
Similarly, all men < 30 years with substantial risk factor
burden using the Framingham risk score model also re-
ported low risk using existing threshold [65]. In addition,
the 10-year predicted risk was also found to be < 10% in
most men < 50 years and most women < 70 years [66].
An approach to lower treatment thresholds would seem
appropriate. A new threshold of ≥ 10% has been recom-
mended for identifying women at high CVD risk for
treatment as it is difficult for a woman below 75 years of
age with several markedly elevated risk factors to exceed
a 10% (let alone a 20%) with the ATP-III risk assessment
tool [16]. The most recent guidelines released by the
American College of Cardiology and American Heart
Association Task Force on Practice Guidelines have rec-
ommended an even lower threshold of 7.5% for the
10-year risk of atherosclerotic CVD for identifying indi-
viduals for treatment [4]. Lower treatment thresholds,
as proposed, would improve the identification of indi-
viduals who require treatment, at the expense of in-
creasing the numbers to treat and increasing associated
costs. Determining thresholds using diagnostic mea-
sures to maximise sensitivity and specificity is still the
preferred approach.
Study strengths and limitations
Our study has limitations. The endpoints of our study
were fatal CVD events established from death certifi-
cates and no incidence data was available. There were
only 28 fatal CVD events among 4487 women in the
10-year follow-up. It is possible that calibration defaults
are present due to differences in the populations used to
develop the Framingham and SCORE models. Though
differences exist, these models have continued to exhibit
calibration when externally validated against other popu-
lations and have been used extensively in the assessment
of CVD risk in previous studies [20,22,54,55]. Partici-
pants were assumed not to have LVH as ECG was not
undertaken in the NHF third Risk Factor Prevalence
Study and this could affect risk prediction of the
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while baseline ECG data to determine LVH were not avail-
able, this is unlikely to have a significant impact on risk
prediction as ECG-diagnosed LVH is very rare in the gen-
eral population without CVD [67]. Only one set of base-
line measurements was recorded for some risk variables
but important variables were measured twice. Menopausal
status of women was not recorded at time of survey. Low
number of CVD events limits the ability for further de-
tailed analyses to assess other risk factors currently not in-
cluded in the risk score models discussed.
Conclusions
In this study, we have provided an independent external
validation of the Framingham risk score model and the
SCORE risk chart for low-risk and high-risk regions
on a cohort of 4487 Australian females. The use of the
Framingham risk score model and SCORE risk chart for
low-risk regions, for predicting the 10-year CVD mortal-
ity risk in the Australian women population is recom-
mended. These models demonstrate good discrimination
and calibration performance. Lower treatment thresh-
olds are needed, in order to better identify individuals
for treatment.
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